FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, namely to means of prevention and treatment of oncological diseases, based on vaccine preparations. Use of an adjuvant-free influenza vaccine with the content of hemagglutinin of the influenza A virus (HHA) from 30 to 120 mcg/dose is proposed as a means of increasing the anti-tumour resistance. A monovalent vaccine against influenza A virus or a trivalent or tetravalent vaccine against influenza A and B viruses is proposed as an anti-influenza vaccine.
EFFECT: preparations containing HHA are effective in treatment of tumours.
4 cl, 3 tbl, 10 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD OF PRODUCING TETRAVALENT SUBUNIT INFLUENZA VACCINE | 2019 |
|
RU2740751C1 |
PENTAVALENT SUBUNIT VACCINE AGAINST RESPIRATORY INFECTIONS AND METHOD OF ITS PREPARATION | 2022 |
|
RU2804948C2 |
METHOD FOR OBTAINING A TETRAVALENT VACCINE FOR THE PREVENTION OF INFLUENZA | 2020 |
|
RU2754398C1 |
METHOD OF PRODUCING ANTIGEN OR ANTIGENS FOR PRODUCTION OF INFLUENZA VACCINE AND A VACCINE BASED ON IT | 2019 |
|
RU2710239C1 |
INFLUENZA VACCINE AND METHOD FOR PREPARING IT | 2010 |
|
RU2446824C2 |
METHOD FOR ASSESSING THE REPRODUCTIVE ACTIVITY OF INFLUENZA VIRUSES IN A TRIVALENT AND QUADRIVALENT LIVE INFLUENZA VACCINE | 2019 |
|
RU2735293C1 |
METHOD OF PREPARING INFLUENZA VACCINE | 2009 |
|
RU2423995C1 |
METHOD OF INCREASING ANTI-TUMOUR RESISTANCE | 2009 |
|
RU2418599C1 |
REASSORTANT RN A9-SWINE A(H7N1) INFLUENZA VIRUS STRAIN FOR NEURAMINIDASE ANTIBODY ASSAY IN INFLUENZA INFECTION AND VACCINATION | 2010 |
|
RU2428476C1 |
INACTIVATED SPLIT INFLUENZA VACCINE AND PREPARATION METHOD THEREOF | 2015 |
|
RU2584594C1 |
Authors
Dates
2021-09-17—Published
2019-12-30—Filed